96934 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
METHODS AND COMPOSITIONS COMPRISING TUMOR SUPPRESSOR GENE THERAPY AND CD122/CD132 AGONISTS FOR THE TREATMENT OF CANCER
#2IMMUNOGENIC CONSTRUCTS AND VACCINES FOR USE IN THE PROPHYLACTIC AND THERAPEUTIC TREATMENT OF INFECTIOUS DISEASES
#3GENE THERAPY
#4MODULAR SELF ASSEMBLY DISASSEMBLY (SADA) TECHNOLOGIES
#5POLYMER MOLECULE, MONOMERIC STRUCTURE AND POLYMERIC STRUCTURE COMPRISING SAME
#6CATENATED VAR2CSA RECOMBINANT PROTEIN, PREPARATION METHOD THEREFOR, AND USE THEREOF
#7METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING CANCER
#8P53 PEPTIDOMIMETIC MACROCYCLES
#9MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE
#10CHIMERIC ANTIGEN RECEPTORS AND METHODS OF MAKING
#11MULTIPLEXED TP53 AND PAN-RAS mRNA CANCER VACCINES
#12p53 VARIANT WITH IMPROVED LIQUID-LIQUID PHASE SEPARATION ABILITY AND ACTIVITY AND USE THEREOF
#13HLA-RESTRICTED EPITOPES ENCODED BY SOMATICALLY MUTATED GENES
#14METHODS AND MATERIALS FOR TARGETING TUMOR ANTIGENS
#15MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS
#16COMPOSITIONS, ASSAYS, AND METHODS FOR TARGETING HDM2 AND HDMX TO REVERSE THE INHIBITION OF p53 IN PEDIATRIC CANCERS
#17METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING CANCER
#18SAFE LENTIVIRAL VECTORS FOR TARGETED DELIVERY OF MULTIPLE THERAPEUTIC MOLECULES
#19Small Molecule Cancer Treatments that Cause Necrosis in Cancer Cells But Do Not Affect Normal Cells
#20METHOD FOR BIOSYNTHESIS OF PROTEIN HETEROCATENANE
#21STABLE FORMULATIONS OF ANTI-CANCER PEPTIDES
#22T CELLS AND CHIMERIC STIMULATING RECEPTORS AND USES THEREOF
#23TREATMENT OF CANCER HARBORING MUTATIONS IN THE TP53 GENE AND/OR POST-TRANSLATIONAL MODIFICATIONS IN THE P53 PROTEIN WITH PARVOVIRUSES
#24NATIVE CELL DERIVED VESICLES CONTAINING TUMOR SUPPRESSOR PROTEINS FOR THERAPY
#25Dendritic cell tumor vaccine and uses thereof
#26HDM-2 TARGETING COMPOSITIONS CAUSE TUMOR CELL NECROSIS RATHER THAN APOPTOSIS OF CANCER CELLS
#27MODULAR SELF ASSEMBLY DISASSEMBLY (SADA) TECHNOLOGIES
#28Neoepitope immunotherapy with APC targeting unit
#29PEPTIDOMIMETIC MACROCYCLES
#30USES OF P53 X-RAY CO-CRYSTAL STRUCTURES
#31p63 inactivation for the treatment of heart failure
#32PEPTIDES AND USE OF SAME IN THE TREATMENT OF DISEASES, DISRODERS OR CONDITIONS ASSOCIATED WITH A MUTANT P53
#33Neoantigen peptide mimics
#34TETRAMERIC PROTEIN SCAFFOLDS AS NANO-CARRIERS OF THERAPEUTIC PEPTIDES FOR TREATING CANCER AND OTHER DISEASES
#35PEPTIDOMIMETIC MACROCYCLES
#36Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
#37Chimeric antigen receptors and methods of making
#38POLYPEPTIDE DELIVERY COMPOSITION
#39MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE
#40MODIFIED MITOCHONDRIA AND USE THEREOF
#41Protein-protein interaction assessed by detecting localized coiled coil subunits
#42Delta133P53Beta and Delta133P53Gamma isoforms are biomarkers of cancer stem cells
#43Small Molecule Cancer Treatments that Cause Necrosis in Cancer Cells But Do Not Affect Normal Cells
#44PANDA AS NOVEL THERAPEUTIC
#45METHODS AND COMPOSITIONS COMPRISING TUMOR SUPPRESSOR GENE THERAPY AND CD122/CD132 AGONISTS FOR THE TREATMENT OF CANCER
#46IN VIVO PRODUCTION OF PROTEINS
#47Methods of reducing neuroinflammation or toxicity induced by amyloid beta (abeta) using glucocorticoid induced leucine zipper (GILZ) analog peptides
#48Cell-Mediated Exosome Delivery
#49Methods and compositions for preventing or treating cancer
#50Methods for treating cancer
#51METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION
#52Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
#53Modular self assembly disassembly (SADA) technologies
#54Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
#55Peptidomimetic macrocycles
#56Peptides capable of reactivating p53 mutants
#57Native cell derived vesicles containing tumor suppressor proteins for therapy
#58Peptide inhibitors of transcription factor aggregation
#59Multimodal cancer therapy comprising chimeric viral/nonviral nanoparticles and anticancer agents
#60SMALL MOLECULE CANCER TREATMENTS THAT CAUSE NECROSIS IN CANCER CELLS BUT DO NOT AFFECT NORMAL CELLS
#61HDM-2 TARGETING COMPOSITIONS CAUSE TUMOR CELL NECROSIS RATHER THAN APOPTOSIS OF CANCER CELLS
#62p53-BAD fusion proteins
#63Peptidomimetic macrocycles
#64Methods for treating cancer
#65Peptides capable of reactivating p53 mutants
#66In vivo production of proteins
#67Compositions and methods comprising permuted protein tags for facilitating overexpression, solubility, and purification of target proteins
#68Gene therapy
#69Cell-penetrating peptide
#70CHIMERIC ANTIGEN RECEPTORS AND METHODS OF MAKING
#71COMPOSITIONS, ASSAYS, AND METHODS FOR TARGETING HDM2 AND HDMX TO REVERSE THE INHIBITION OF p53 IN PEDIATRIC CANCERS
#72Methods and compositions for preventing or treating cancer
#73Methods of using therapeutic p53 peptides
#74Peptidomimetic macrocycles
#75Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant P53
#76Methods of treating tumors and cancer, and identifying candidate subjects for such treatment
#77Modified Polynucleotides for the production of biologics and proteins associated with human disease
#78Stabilized compounds having secondary structure motifs
#79METHODS AND COMPOSITIONS FOR ENHANCING GENE EDITING
#80P53 biomarkers
#81Structure-based peptide inhibitors of P53 aggregation as a new approach to cancer therapeutics
#82Combination immunotherapy for treating cancer
#83p63 inactivation for the treatment of heart failure
#84ENZYMATICALLY-CLEAVABLE PEPTIDE AMPHIPHILES
#85Peptides capable of reactivating p53 mutants
#86Method for preparing peptide-polymer conjugate with stabilized α-helix secondary structure and peptide-polymer conjugate prepared thereby
#87Peptides and uses thereof
#88Methods for treating cancer
#89Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
#90Delta133p53beta and delta133p53gamma isoforms are biomarkers of cancer stem cells
#91In vivo production of proteins
#92Peptidomimetic macrocycles
#93Stabilized compounds having secondary structure motifs
#94Stabilized P53 peptides and uses thereof
#95Stitched polypeptides
#96Peptides for treating cancer
#97TARGETING P53 AND ITS DNA-BINDING DOMAIN
#98OLIGOMERIZATION DOMAIN OF P53 TO BYPASS THE DOMINANT-NEGATIVE EFFECT OF MUTANT
#99Three-helix bundle protein and use thereof
#100Peptidomimetic macrocycles
#101Peptides capable of reactivating p53 mutants
#102PROTEASOME INHIBITORS AND USES THEREOF
#103Compositions comprising serum albumin and p53 peptides fusion proteins
#104Modified polynucleotides for the production of biologics and proteins associated with human disease
#105Structure-based peptide inhibitors of P53 aggregation as a new approach to cancer therapeutics
#106FUSION POLYNUCLEOTIDES AND FUSION POLYPEPTIDES ASSOCIATED WITH CANCER AND PARTICULARLY MELANOMA AND THEIR USES AS THERAPEUTIC AND DIAGNOSTIC TARGETS
#107Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer
#108iASPP phosphorylation and metastatic potential
#109DOMINANT NEGATIVE TRANSCRIPTION FACTOR FOR ANTAGONIZING ONCOGENIC TRANSCRIPTION FACTORS VIA MULTIMERIZATION
#110Stabilized p53 peptides and uses thereof
#111Leucine zipper variant and use thereof
#112Peptidomimetic macrocycles
#113MEMBRANE RESIDENT PEPTIDE IN ANTI-CANCER PEPTIDES CAUSES TUMOR CELL NECROSIS RATHER THAN APOPTOSIS OF CANCER CELLS
#114Neurotoxins exhibiting shortened biological activity
#115Stabilized compounds having secondary structure motifs
#116Stitched polypeptides
#117Therapeutic applications of P53 isoforms in regenerative medicine, aging and cancer
#118Peptidomimetic macrocycles
#119Proteasome inhibitors and uses thereof
#120Stabilized compounds having secondary structure motifs
#121PEPTIDE ABLE TO DISRUPT THE PROTEIN COMPLEX BETWEEN THE HIS273 MUTADED P53 PROTEIN AND THE ONCOSUPPRESSIVE P73 PROTEIN IN TUMOR CELLS AND THERAPEUTIC USES THEREOF
#122NOVEL HUMAN P53 SPLICE VARIANT DISPLAYING DIFFERENTIAL TRANSCRIPTIONAL ACTIVITY
#123Membrane resident peptide in anti-cancer peptides causes tumor cell necrosis rather than apoptosis of cancer cells
#124P53 FUSION PROTEINS AND METHODS OF MAKING AND USING THEREOF
#125Cell permeable p53 recombinant protein, polynucleotide encoding the same, and anti-cancer composition containing the same as active ingredient
#126Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
#127Methods for producing microRNAs
#128PROTEASOME INHIBITORS AND USES THEREOF
#129Recombinant adenovirus target-oriented co-expressing human p53 and p53aip1
#130Method of detecting tumor-associated DNA in plasma or serum with a premalignant solid tumor
#131Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer
#132Method of detecting tumor-associated hypermethylated DNA in plasma or serum
#133Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
#134FUSION PROTEIN COMPRISING UBIQUITIN OR UBIQUITIN-LIKE PROTEIN, MEMBRANE TRANSLOCATION SEQUENCE AND BIOLOGICALLY ACTIVE MOLECULE AND USE THEREOF
#135COMPOSITIONS AND METHODS FOR THERAPEUTIC USE
#136P53 biomarkers
#137REGULATION OF LITAF MODULATED CYTOKINE PRODUCTION BY A NOVEL P53 SHORT PEPTIDE
#138Method of detecting tumor-associated DNA in plasma or serum from humans without cancer
#139Mosaic knockout mouse tumor models and methods or use
#140COMPOSITIONS AND METHODS FOR CANCER GENE DISCOVERY
#141Transgenic Animal Model of Cancer and Methods of Use
#142Stabilized compounds having secondary structure motifs
#143Human p51 genes and gene products thereof
#144P53 peptide vaccine
#145Stitched polypeptides
#146SAFE LENTIVIRAL VECTORS FOR TARGETED DELIVERY OF MULTIPLE THERAPEUTIC MOLECULES
#147Stabilized p53 peptides and uses thereof
#148CRYSTAL STRUCTURE OF P53 MUTANTS AND THEIR USE
#149METHOD FOR THE PRODUCTION AND PURIFICATION OF RETROVIRAL VECTORS
#150RECOMBINANT ADENOVIRUS COMPRISING RECOMBINANT khp53 GENE AND THE PREPARATION METHOD AND USES THEREOF
#151Evaluation of diseases and conditions associated with translocated genes using plasma or serum DNA
#152Peptide able to break the m-p53/p63, m-p53/p73 and m-p53/respective isoform proteins complex formed in the tumor cells and uses thereof in the pharmacological field
#153Modified KSA and Uses Thereof
#154Human p51 genes and gene products thereof
#155Methods for producing microRNAs
#156Methods for Detecting Papillomavirus DNA in Blood Plasma and Serum
#157Novel Neural Cell Specific Promoter And Baculovirus And Method For Gene Delivery
#158COMPOSITIONS AND METHODS FOR THERAPEUTIC USE
#159Peptides for inhibiting MDM2 function
#160COMPUTER GENE
#161Oncolytic Adenovirus Armed with Therapeutic Genes
#162METHOD FOR SELECTIVELY TRANSDUCING PATHOLOGIC MAMMALIAN CELLS USING A TUMOR SUPPRESSOR GENE
#163COMBINED TUMOR SUPPRESSOR GENE THERAPY AND CHEMOTHERAPY IN THE TREATMENT OF NEOPLASMS
#164Ligands and libraries of ligands
#165Methods of screening for supracolonic neoplasms based on stool samples containing a nucleic acid marker indicative of a neoplasm
#166Methods for selecting cancer vaccine therapies using extracellular DNA
#167Methods for selecting monoclonal antibody therapies using extracellular DNA
#168Binding peptidomimetics and uses of the same
#169Methods and compositions for modulating apoptotic pathways
#170Peptides selectively lethal to malignant and transformed mammalian cells
#171Peptides selectively lethal to malignant and transformed mammalian cells
#172Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assay
#173Method for the production and purification of adenoviral vectors
#174Means and methods for producing a stabilized cell of interest
#175Induction of Cellular Senescence by Cdk4 Disruption for Tumor Suppression and Regression
#176Adenoviral vectors having a protein IX deletion
#177RECOMBINANT ADENOVIRAL VECTORS AND METHODS OF USE
#178Peptides selectively lethal to malignant and transformed mammalian cells
#179Method for selectively transducing pathologic mammalian cells using a tumor suppressor gene
#180Modified vaccinia ankara expressing P53 in cancer immunotherapy
#181Recombinant p53 adenovirus methods and compositions
#182C-terminal p53 palindromic peptide that induces apoptosis of cells with aberrant p53 and uses thereof
#183Expression of cyclin G1 in tumors
#184Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
#185Method for the production and purification of adenoviral vectors
#186Adenoviral vectors having a protein IX deletion
#187COMBINED TUMOR SUPPRESSOR GENE THERAPY AND CHEMOTHERAPY IN THE TREATMENT OF NEOPLASMS
#188Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids
#189Methods for producing microRNAs
#190Recombinant adenoviral vector and method of use
#191Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
#192Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assays
#193Adenoviral vectors having a protein IX deletion
#194Methods for enhancing viability
#195Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assays
#196Adenoviral vectors having a protein IX deletion
#197Adenoviral vectors having a protein IX deletion
#198Methods and compositions comprising DNA damaging agents and p53
#199Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assays
#200Adenoviral vectors having a protein IX deletion
#201Method for detecting loss of wild-type p53
#202Transcriptional factor inducing apoptosis in cancer cell
#203Recombinant adenoviral vectors and methods of use
#204Use of c-Jun or c-Jun activating agents such as UV or c-Jun N-terminal kinases (JNKs) for treating cancer
#205Method for mitochondrial targeting of p53
#206Human p51 genes and gene products thereof
#207Method for purifying adenoviruses
#208Peptide delivery
#209Immunoglobulin construct containing tumor- specific p53bp2 sequenes for eliciting an anti-tumor response
#210Adenoviral vectors having a protein IX deletion
#211Hla-a1,-a2,-a3,-a24,-b7, and-b44 tumor associated antigen peptides and compositions
#212Hla binding peptides and their uses
#213Kits for the detection of target sequences
#214Human p53 splice variant displaying differential transcriptional activity
#215Adenoviral vectors having a protein IX deletion
#216Methods and compositions for the diagnosis and treatment of cancer
#217Adenoviral vectors having a protein IX deletion
#218Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
#219Slc2as as modifiers of the p53 pathway and methods of use
#220Stabilized compounds having secondary structure motifs
#221Method of reducing side effects of cancer therapy using p53 recombinant adenovirus
#222Peptides selectively lethal to malignant and transformed mammalian cells
#223Viruses with enhanced lytic potency
#224In vivo homologous sequence targeting in cells
#225Inducing cellular immune responses to p53 using peptide and nucleic acid compositions
#226Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assays
#227Method of extending life span
#228Nucleic acid detection kits
#229Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
#230Polypeptides (MBP1) capable of interacting with oncogenic mutants of the p53 protein
#231Assay and treatment
#232Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assay
#233Method for the production and purification of adenoviral vectors
#234Methods and compositions comprising DNA damaging agents and p53
#235Method for selectively transducing pathologic mammalian cells using a tumor suppressor gene
#236Inhibition of DNA modulation caused by mutated p53
#237Global suppressors of p53 mutations
#238p53 treatment of papillomavirus and carcinogen-transformed cells in hyperplastic lesions
#239Tumor suppression through bicistronic co-expression of p53 and p14ARF
#240Adenoviral vectors having a protein IX deletion
#241Stabilizing molecule
#242Composition for regulating production of proteins